Condition (MeSH)
Lichen Sclerosus et Atrophicus
ClinicalTrials.gov lists 29 trials for Lichen Sclerosus et Atrophicus or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
29 of the 29 trials are tagged with Lichen Sclerosus et Atrophicus itself; the rest are tagged with a narrower condition beneath it.
When did Lichen Sclerosus et Atrophicus trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lichen Sclerosus et Atrophicus trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 3 |
| Not applicable | 12 |
| Observational | 10 |
How many Lichen Sclerosus et Atrophicus trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 13 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lichen Sclerosus et Atrophicus trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| 1st Federal Budgetary Healthcare Institution Volga District Medical Center | 1 |
| Incyte Corporation | 1 |
| Juna d.o.o. | 1 |
| LEO Pharma | 1 |
Which drugs are being tested for Lichen Sclerosus et Atrophicus? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Delgocitinib | 1 |
| Clobetasol | 1 |
| Nemolizumab | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [PRP] platelet rich plasma | 2 |
| No Interventions | 1 |
| Clobetasol 0.05% ointment | 1 |
| Ruxolitinib 1.5% Cream | 1 |
| Ruxolitinib Topical Cream | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lichen Sclerosus et Atrophicus trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| COVID-19 pneumonia | 1 | 1 |
Which publications cover Lichen Sclerosus et Atrophicus? (42)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Systemic Therapy for Lichen Sclerosus: A Systematic Review. | Journal of lower genital tract disease | 2024 | Yes |
| Treatment of Refractory Vulvar Lichen Sclerosus With Methotrexate. | Journal of lower genital tract disease | 2024 | Yes |
| EuroGuiderm guideline on lichen sclerosus-introduction into lichen sclerosus. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2024 | Yes |
| EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2024 | Yes |
| Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus. | Experimental dermatology | 2023 | Yes |
Showing 5 of 42 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.